Reimagining Biopharma: Precision Medicine, Patients, and Purpose with Takeda CEO-Elect

The podcast features Julie Kim, Interim Head of Global Portfolio Division at Takeda, who will be the next President and CEO of Takeda in June 2026. Kim discusses key trends shaping the biopharmaceutical industry, including the acceleration of scientific discovery through AI, which is refining medicines and improving efficiency. A major challenge lies in the complexity of the U.S. market and access to medicines, impacting drug pricing and innovation. Kim emphasizes the need for market innovation alongside scientific advancements to realize precision medicine, tailoring treatments to individual patients. She also shares pivotal career moments, including her decision to prioritize her son's well-being over an executive role, and highlights the importance of sponsorship in career advancement.